Navigating Compounding Peptides and GLP-1s Through Regulations

Lucas Morgan, Esq, and Dae Lee, PharmD, Esq, CPBS, both shareholders and pharmacy benefit managers (PBMs) and pharmacy practice group cochairs at Buchanan Ingersoll & Rooney PC, delivered a session at the Total Pharmacy Solutions Summit. Their presentation, “Compounding Peptides and GLP-1s: Opportunities and Risks for Pharmacies in 2026,” provided a legal road map for pharmacies looking to enter the booming market for weight-loss and wellness treatments while avoiding the crosshairs of federal and state regulators.

The surge in interest in peptides and glucagon-like peptide-1 (GLP-1) products such as semaglutide and tirzepatide is driven largely by a shortage of commercially available options. This environment introduced patients—many for the first time—to the concept of compounding as a way to access medication when branded versions are unavailable. Morgan and Lee noted that although patient demand is outpacing regulatory clarity, this creates an opportunity for independent pharmacies to diversify their portfolios and shift toward cash-based revenue models, reducing their reliance on traditional PBM insurance models.

Morgan and Lee highlighted 2 significant FDA statements issued in April 2026 aimed at “clarifying” policies as GLP-1 supplies stabilized. Morgan explained that these statements were effectively signals or warnings to the industry. The FDA restated well-established laws, including that once a shortage is declared over, a 503A pharmacy cannot compound a product that is essentially a copy of a commercially available drug unless a patient-specific, clinically significant difference exists for the compounded version.

The Legal Fork in the Road: 503A vs 503B

A common pitfall identified by Lee is the “business model that wants the economics of broad distribution but the regulatory posture of traditional patient-specific compounding.”

• 503A pharmacies: These must operate pursuant to a valid, patient-specific prescription. They must ensure the product is not essentially a copy and that they are sourcing active pharmaceutical ingredients (APIs) from reputable, FDA-registered wholesalers with a valid certificate of analysis (COA).
• 503B outsourcing facilities: Designed for office use and bulk distribution, these facilities do not require patient-specific prescriptions but must meet rigorous Current Good Manufacturing Practice standards and federal reporting requirements.

The FDA is focused heavily on policing marketing practices. Morgan warned that pharmacies must never suggest that compounded products are FDA approved, as this is a “huge no-no.” Avoid using phrases like FDA-regulated pharmacies to imply approval, and never make clinical claims about a compounded drug’s efficacy in treating specific conditions. Furthermore, although telehealth offers a valuable access point, pharmacies must ensure their contracts with telehealth providers are reviewed by legal counsel to ensure the consistency through the chain of operations—meaning the doctor-patient relationship and the prescription must be legitimate before the pharmacy fills the order.

Key Takeaways From the Presentation

• In a 503A setting, a valid prescription based on a patient-specific need is the most critical factor for compliance.
• Pharmacies must have immediate access to COAs, standard operating procedures, and clinical rationale for compounding copies.
• State boards of pharmacy often mirror FDA rules but are more localized and can enforce them more strictly, especially regarding nonresident permits and individual pharmacist licensure.
• Disciplinary action from a state board regarding compounding must usually be reported to PBMs and other state boards, potentially jeopardizing the pharmacy’s entire business.
• Pharmacists in charge have a professional duty to demand access to a pharmacy’s policies. If a practice feels questionable and remains unchanged, they should consider stepping away to protect their livelihood.

The experts concluded by emphasizing that investing in legal compliance up front is significantly cheaper than defending against an enforcement action later. As the GLP-1 market continues to evolve, pharmacies must balance the undeniable business opportunities with a strictly legally compliant model. By vetting marketing, securing a high-quality API, and maintaining rigorous recordkeeping, pharmacies can safely serve the growing patient demand for personalized care.